Development of a database to collect clinical data, and where available associated tumour tissue samples, from patients with Renal Cell Carcinoma (KRAB).

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12618000929202

Acronym

KRAB

Enrollment

1444

Registered

2018-06-01

Start date

2018-07-06

Completion date

2032-12-31

Last updated

2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to determine whether certain biomarkers have an impact on the effectiveness of treatment for kidney cancer. Who is it for? You may be eligible for this study if you are over the age of 18 and have been diagnosed with kidney cancer. Study details If there is left over tissue after planned medical procedures then a sample of this tissue will be kept. The tissue samples will then be tested to determine how the cells, genes and immune system interact with the cancer and whether these relate to treatment results. It is hoped that this research will help us to better understand why some kidney cancers are more aggressive than other and also why some treatments work better in some patients than others.

Interventions

Enrolled patients diagnosed with metastatic renal cell carcinoma will undergo collection of clinical data and archival tumour specimens. Clinical data collected includes: patient demographics and characteristics, disease clinicopathological and molecular features, treatment history, outcomes and survival. Data will be collected regularly throughout the patient's treatment and follow up until death. Where applicable, archival tumour specimens will also be utilised.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Any patient 18 years old or above with metastatic RCC

Exclusion criteria

None

Outcome results